

15/ Prior art Wast

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Wolfgang HEIL et al.

Group Art Unit: 1615

Serial No.:

09/757,688

Examiner: L.S. CHANNAVAJJALA

Filed:

January 11, 2001

For:

DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) hereby disclose the information listed in the attached form	PTO	1-144	19.
		_	_

	Copies of materials listed but not attached were cited in parent application Seria				
	No; see 37 C.F.R. § 1.98(d).				

Copies of materials listed but not attached were cited in an International Search Report dated _____; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed _____.

ADDITIONAL INFORMATION

LANGUAGE

All listed materials are in the English language; see 37 C.F.	F.R. § 1.98.
---	--------------

□ Non-English language references:

	The reference(s):	in the	English-language	is (are) indicated by
_ comm	ercial data bases to corre	spond to	the reference(s):	, respectively.

(An) English-language translation(s) of the references: is (are) provided.

A commercial English-language abstract of reference(s) is (are) provided.

An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

180.00 OP

05/31/2002 RMEBRAHT 00000056 09757688

FEES No fee is required for this Information Disclosure Statement because: This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application; This Information Disclosure Statement is being filed before the mailing of a first action on the merits; This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below. This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i). A fee is required for this Information Disclosure Statement: \boxtimes This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p). This Information Disclosure Statement is being filed after the mailing date

CERTIFICATION

Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

fee set forth in § 1.17(p) and a certification below.

of a final rejection or a notice of allowance under § 1.311 or an action that closes

prosecution, but before the payment of the issue fee, and is accompanied by the

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$180.00. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

John A. Søpp, Reg. No. 33,103 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: PLOVIN-2A

Date: May 17, 2002

JAS:ghp